Scholarlink

Purpose <p>Benign breast disease (BBD), particularly with proliferative changes, is a risk factor for breast cancer (BC) development in average risk women. There is a paucity of data on high-risk, <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants (PVs) carriers.</p> Methods <p>Female <i>BRCA1</i> and <i>BRCA2</i> PV carriers treated at the Meirav Clinic, Sheba Medical Center between May 2011 and December 2024 were eligible. Data on in-hospital breast biopsies were retrieved following an ethically approved protocol. Statistical analyses included <i>χ</i><sup>2</sup> test (categorical variables) Mann–Whitney <i>U</i> test (continuous variables) and logistic regression for multivariate analysis.</p> Results <p>Overall, 1466 women (849 <i>BRCA1</i> PV carriers) were monitored over 10,113 women/years. A total of 1453 biopsies were carried out in 454 participants (range 1–8 biopsies), with the majority (76.3%) benign and 242 (16.6%) malignant. Rates of BC in women undergoing at least two benign biopsies were correlated with the number of biopsies, being an older <i>BRCA1</i> PV carrier, whereas having been diagnosed with fibroadenoma—seems not to increase BC risk.</p> Conclusions <p>In Israeli <i>BRCA</i> PV carriers, the number of biopsies, <i>BRCA1</i> PV carriership were associated with an increased risk for developing BC, whereas fibroadenoma does not increase that risk. It is imperative to validate these preliminary observations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Breast biopsies and breast cancer risk in Israeli BRCA germline pathogenic variant carriers

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月22日

查看全文
  • Dana Madorsky Feldman,
  • Miri Sklair-Levy,
  • Yael Laitman,
  • Renata Faermann,
  • Noam Nissan,
  • Osnat Halshtok Neiman,
  • David Samoocha,
  • Yael Yagil,
  • Eitan Friedman

摘要

Purpose

Benign breast disease (BBD), particularly with proliferative changes, is a risk factor for breast cancer (BC) development in average risk women. There is a paucity of data on high-risk, BRCA1 and BRCA2 pathogenic variants (PVs) carriers.

Methods

Female BRCA1 and BRCA2 PV carriers treated at the Meirav Clinic, Sheba Medical Center between May 2011 and December 2024 were eligible. Data on in-hospital breast biopsies were retrieved following an ethically approved protocol. Statistical analyses included χ2 test (categorical variables) Mann–Whitney U test (continuous variables) and logistic regression for multivariate analysis.

Results

Overall, 1466 women (849 BRCA1 PV carriers) were monitored over 10,113 women/years. A total of 1453 biopsies were carried out in 454 participants (range 1–8 biopsies), with the majority (76.3%) benign and 242 (16.6%) malignant. Rates of BC in women undergoing at least two benign biopsies were correlated with the number of biopsies, being an older BRCA1 PV carrier, whereas having been diagnosed with fibroadenoma—seems not to increase BC risk.

Conclusions

In Israeli BRCA PV carriers, the number of biopsies, BRCA1 PV carriership were associated with an increased risk for developing BC, whereas fibroadenoma does not increase that risk. It is imperative to validate these preliminary observations.